Acral erythema has been reported in patients receiving sustained dosing (or those who could use prolonged exposure) of the cytotoxic drugs fluorouracil, capecitabine, cytarabine, sorafenib, sunitinib, and pegylated liposomal doxorubicin.
Tingling and/or numbness (aka paresthesias) in the palms and soles are the first symptoms, which then evolve into painful well-demarcated symmetrical swelling and red plaques, followed by peeling and symptom resolution.
Acral erythema, with similar clinical and histological features, can also occur after bone marrow transplant due to dermatologic manifestations of graft vs. host disease.
Symptoms generally resolve 1 to 2 weeks after discontinuing chemotherapy. Results from small clinical studies suggest that corticosteroids may be helpful in relieving symptoms, and that frequent applications of emollients to the hands and feet may help prevent the disorder. The offending anticancer drug may be reintroduced at lower doses once the side effects have abated.
Acral erythema is an adverse drug reaction to chemotherapy that can occur days to months after a patient begins treatment and results in reddening, swelling and desquamation of the skin, often of the palms and soles. The syndrome is also referred to as hand-foot syndrome, palmar-plantar erythrodysesthesia, and Burgdorf’s reaction.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|